This review summarizes recent advances in the clinical applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond their established role in glycemic control for type 2 diabetes (T2DM)
These pressures, alongside a frequent lack of practitioner education about integrating lifestyle management in medicine, have created a dearth of implemented behavioral and lifestyle counseling, accessible and effective referral programs, and integration into existing care delivery systems
In addition, the latest guidelines classify microglial states into five major phenotypes: homeostatic, DAM-like, HLA/MHC class II, CRM or inflammatory, and interferon (IRM or IFN) clusters [105]
However, there is no clear evidence suggesting that the ingredients in the natural GLP-1 patches activate the GLP-1 hormone when delivered transdermally
Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2